<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996771</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-L103</org_study_id>
    <nct_id>NCT04996771</nct_id>
  </id_info>
  <brief_title>Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer</brief_title>
  <official_title>A Phase Ⅰb/II Study of Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in Patients With Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluates the effectiveness and safety of Surufatinib combined with chemotherapy plus&#xD;
      Toripalimab or not for the first-line treatment of SCLC, and maintenance therapy are&#xD;
      Surufatinib combined with Toripalimab or not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress Free Survival(PFS)</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival(OS)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Small Cell Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Surufatinib Combined With Toripalimab and Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Surufatinib Combined With Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib,Etoposide,Cisplatin,Toripalimab</intervention_name>
    <description>In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.&#xD;
At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed.</description>
    <arm_group_label>Surufatinib Combined With Toripalimab and Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib,Etoposide,Cisplatin</intervention_name>
    <description>In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.&#xD;
At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed.</description>
    <arm_group_label>Surufatinib Combined With Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have the ability to understand and voluntarily sign informed consent;&#xD;
&#xD;
          2. Age: 18-75 years old;&#xD;
&#xD;
          3. Expected survival period ≥ 3 months;&#xD;
&#xD;
          4. Extensive-stage small cell lung cancer confirmed by histology ;&#xD;
&#xD;
          5. According to the RECIST 1.1 standard, the patient has at least one target lesion with&#xD;
             a measurable diameter;&#xD;
&#xD;
          6. ECOG PS: 0-2;&#xD;
&#xD;
          7. Laboratory test indicators must meet the following requirements: Hematology: white&#xD;
             blood cells ≥4.0×10^9/L, neutrophils ≥2.0×10^9/L, platelet count ≥100×10^9/L,&#xD;
             hemoglobin ≥90g/L. Liver function: serum bilirubin is lower than 1.5 times the maximum&#xD;
             normal value; for patients without liver metastasis: ALT and AST are lower than 2.5&#xD;
             times the maximum normal value; for patients with liver metastasis: ALT and AST are&#xD;
             lower than 5 times the maximum normal value ; Measured or calculated creatinine&#xD;
             clearance: According to the Cockcroft-Gault formula (using actual body weight),&#xD;
             patients receiving cisplatin treatment&gt;60mL/min, and patients receiving carboplatin&#xD;
             treatment&gt;45mL/min;&#xD;
&#xD;
          8. Good compliance and follow-up;&#xD;
&#xD;
          9. The urine or serum pregnancy test results of premenopausal women were negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who have previously received VEGFR-TKI (such as Regorafenib, etc.) ;&#xD;
&#xD;
          2. Patients with symptomatic brain metastases;&#xD;
&#xD;
          3. People with hypertension who cannot be well controlled by double antihypertensive drug&#xD;
             (systolic blood pressure≥140 mmHg, diastolic blood pressure≥90 mmHg);&#xD;
&#xD;
          4. Urine routine test showed urine protein ≥++ and confirmed 24-hour urine protein&#xD;
             quantification&gt;1.0g;&#xD;
&#xD;
          5. Cardiovascular disease history: congestive heart failure&gt; New York Heart Association&#xD;
             (NYHA) standard II, patients with active coronary artery disease (those with&#xD;
             myocardial infarction 6 months before enrollment can be enrolled), arrhythmia&#xD;
             requiring treatment (Allows to take beta blockers or digoxin);&#xD;
&#xD;
          6. Active severe clinical infections (&gt;NCI-CTCAE 5.0 version 2 infection criteria),&#xD;
             including tuberculosis (clinical evaluation, including clinical history, physical&#xD;
             examination, imaging findings and TB examination in line with local clinical&#xD;
             practice), hepatitis B (known HBV Surface antigen [HbsAg] positive), hepatitis C or&#xD;
             human immunodeficiency virus (HIV 1/2 antibody positive). Patients who have previously&#xD;
             had HBV infection or have been cured (defined as the presence of hepatitis B core IgG&#xD;
             antibodies and the absence of HBsAg) are eligible. Hepatitis C virus (HCV)&#xD;
             antibody-positive patients are only eligible if the HCV RNA polymerase chain reaction&#xD;
             is negative;&#xD;
&#xD;
          7. Patients with bleeding tendency or coagulation disorders, (14 days before&#xD;
             randomization must meet: INR is within the normal range without the use of&#xD;
             anticoagulants);&#xD;
&#xD;
          8. In the past 2 years, there are active autoimmune diseases that require systemic&#xD;
             treatment (such as corticosteroids or immunosuppressive drugs), and related&#xD;
             alternative treatments (such as thyroxine, insulin, or physiological corticosteroid&#xD;
             replacement for renal or pituitary insufficiency) are allowed treatment);&#xD;
&#xD;
          9. Those who have received live vaccination within 4 weeks before the start of treatment;&#xD;
&#xD;
         10. Those who had suffered from tumors other than small cell lung cancer within 5 years&#xD;
             before being enrolled in this study. Except: cervical carcinoma in situ, cured basal&#xD;
             cell carcinoma, cured bladder epithelial tumor;&#xD;
&#xD;
         11. Severe unhealed wounds, ulcers or fractures;&#xD;
&#xD;
         12. Patients who are pregnant or breastfeeding ;&#xD;
&#xD;
         13. Any unstable conditions may endanger the safety of patients and affect their&#xD;
             compliance with research;&#xD;
&#xD;
         14. Researchers think it is inappropriate to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wenfeng Fang, MD.</last_name>
    <phone>+86-15322302066</phone>
    <email>fangwf@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guang Dong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wenfeng Fang, MD.</last_name>
      <phone>+86-15322302066</phone>
      <email>fangwf@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

